Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health reports developments tied to its healthcare services business for people with complex conditions. Company news commonly covers operating and financial results, customer activity with health plans and providers, and the Performance Suite contract model used in its specialty care operations.
Recurring updates also include Evolent's complex specialty care focus in oncology, cardiology and musculoskeletal conditions, management participation in healthcare investor conferences, leadership appointments, board and compensation matters, and equity-award disclosures under NYSE rules.
Evolent (NYSE: EVH) reported Q2 2026 revenue of $652.5 million, up from $444.3 million in Q2 2025, with a net loss attributable to common shareholders of $28.4 million versus $51.1 million a year earlier, improving its net loss margin to (4.3)% from (11.5)%. Adjusted EBITDA was $28.1 million with a 4.3% margin, down from $37.5 million and 8.5%.
The company highlighted a medical expense ratio of 95.3% and total cash and equivalents of $115.7 million. Evolent raised full‑year 2026 revenue guidance to $2.6–$2.7 billion and tightened Adjusted EBITDA guidance to $120–$135 million. For 2027, management expects revenue growth of over 25% versus 2026 and an Adjusted EBITDA midpoint at or above $150 million. New partnerships include an Oncology Performance Suite contract expected to launch by December 2026, covering about 1.5 million lives and targeted to generate roughly $300 million in annualized revenue, subject to regulatory approvals.
Evolent Health (NYSE:EVH) announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before market open, followed by a conference call at 8 a.m. ET.
The live webcast and a 90-day audio replay will be available on Evolent’s investor relations website.
Quest Analytics appointed Chris Lance as Chief Product Officer on May 12, 2026. He will lead vision, strategy, and execution across the full product portfolio, focusing on innovation and AI-powered solutions that help health plans build, manage, model, and optimize provider networks.
Lance brings over 20 years of product and technology leadership, including CPO roles at Edifecs and Avalon Healthcare Solutions, and senior product positions at Evolent Health and Change Healthcare.
Evolent Health (NYSE: EVH) reported Q1 2026 revenue of $496.2M and a GAAP net loss of $26.6M. Adjusted EBITDA was $22.1M (4.4% margin). Cash totaled $142.0M. Company reiterated 2026 guidance: $2.4B–$2.6B revenue and $110M–$140M Adjusted EBITDA. Two new agreements include a ~4.5M‑lives imaging rollout and an oncology/cardiology expansion expected to generate >$200M annual revenue, both subject to state regulatory approvals. Management cited on‑time oncology launches and focus on AI and market extension.
Evolent (NYSE: EVH) will release its first quarter 2026 financial results on Thursday, May 7, 2026, before market open, followed by a conference call at 8 a.m. ET.
Shareholders can listen via live webcast on Evolent's investor relations website. Analysts may dial the provided US or international numbers and should reference the "Evolent call" 15 minutes prior. An audio replay will be available on the investor site for 90 days.
Evolent (NYSE: EVH) appointed Archie Mayani as chief product officer effective March 19, 2026. Mayani brings more than 20 years of product, AI and health‑tech leadership across GHX, Change Healthcare, Optum/UnitedHealth Group and Amazon.
She has led AI initiatives for supply‑chain resilience, clinical decision support, revenue cycle and population health, and received industry awards in 2023 and 2025.
Foodsmart (EVH) appointed Dr. Toyin Ajayi, co-founder and CEO of Cityblock Health, to its Board of Directors on March 18, 2026. Dr. Ajayi brings value-based care experience focused on Medicaid and dually eligible populations. Foodsmart serves more than 3 million members and aims to embed nutrition into clinical care.
Evolent Health (NYSE: EVH) said members of its executive management team will participate in investor conferences in March 2026, including Cowen on March 3 and Oppenheimer on March 17. A live audio-only webcast and replay will be available in the Events and Presentations section of the company investor relations website.
Presentation webcast times will be posted on the website as they become available.
Evolent Health (NYSE: EVH) reported Q4 2025 revenue of $468.7M and full-year 2025 revenue of $1.876B. GAAP net loss was $429.1M in Q4 and $579.4M for 2025; adjusted EBITDA was $37.8M in Q4 and $151.2M for 2025.
The company ended 2025 with $151.9M cash, projects 2026 revenue of $2.4B–$2.6B, adjusted EBITDA guidance of $110M–$140M, and expects to capitalize $25M–$35M in software development.
Evolent Health (NYSE: EVH) will release its 2025 fourth quarter and year-end financial results on Tuesday, February 24, 2026 after market close, followed by a conference call at 5:00 p.m. ET. Participants can listen via the company's investor relations website and analysts may dial in to ask questions. An audio playback will be available on the investor site for 90 days after the call.